A Phase 2 Open-Label Study to Evaluate Etavopivat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)

Contact:

212-342-5162

NCT Number:

NCT05568225

Protocol:

AAAU3328

Study Status:

Active/Enrolling

Population:

Adult

Phase:

II

The purpose of this study is to evaluate the effects of etavopivat, good and bad, in individuals with myelodysplastic syndrome (MDS).

Are you Eligible? (Inclusion Criteria)

  • Are you 18 years of age or older? Do you have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2? Can you comply with the procedures in this study, which include taking the study drug and extra clinic visits and procedures?

Specialty Area(s)

Myelodysplastic Syndrome

Principal Investigator

Joseph G. Jurcic, MD

Profile Headshot
  • Director, Hematologic Malignancies Section

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
Open location in Google Maps